AlloVir
AlloVir is a biotechnology company specializing in the development of allogeneic, virus-specific T cell therapies designed to treat and prevent viral infections in immunocompromised patients, with a headquarters in Waltham, MA.
Services
AlloVir specializes in the development of allogeneic, virus-specific T cell (VST) therapies. These therapies focus on treating and preventing viral infections in immunocompromised patients. The company harnesses a proprietary platform to create off-the-shelf VSTs aimed at restoring immunity in individuals with T cell deficiencies.
US Headquarters
AlloVir's US headquarters is located at 1100 Winter Street, Waltham, MA 02451. This location serves as the central hub for the company's operations, including research, development, and administrative activities.
Product Pipeline
AlloVir's product pipeline features several promising therapies: Posoleucel, ALVR106, and ALVR107. Posoleucel is designed to target six significant viral pathogens, including adenovirus, BK virus, cytomegalovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. ALVR106 aims at pathogens such as human metapneumovirus, influenza, parainfluenza virus, and respiratory syncytial virus while ALVR107 is an investigational therapy intended to treat chronic hepatitis B virus (HBV) infections. ALVR107 is currently in preclinical and IND-enabling studies to support its progression to proof-of-concept studies.
Viral Pathogens Targeted
AlloVir's therapies aim to combat a range of viral pathogens. Posoleucel is developed to target viruses such as adenovirus, BK virus, cytomegalovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. ALVR106 addresses human metapneumovirus, influenza, parainfluenza virus, and respiratory syncytial virus. Additionally, ALVR107 focuses on hepatitis B virus with aspirations of treating and potentially curing chronic HBV infections.
Research and Development
AlloVir is actively engaged in research and development to advance its therapeutic pipeline. The company is conducting preclinical and IND-enabling studies for ALVR107, which supports the transition into a proof-of-concept study. Through its proprietary platform, AlloVir continually develops VSTs to address various viral infections in patients with T cell deficiencies.